On September 25, 2025, former U.S. President Donald Trump dropped a bombshell in global trade circles: starting October 1, his administration plans to impose a 100 % tariff on all branded or patented pharmaceutical imports, unless companies are already building manufacturing plants in the United States. The announcement instantly rattled investor sentiment in India, sending major pharma stocks like Sun Pharma, Biocon, Cipla, Dr. Reddy’s, and others sharply lower and sparking jitters across Dalal Street.
What’s in the Tariff and What’s Exempt
Trump’s directive targets branded or patented medicines, not generic drugs, though whether that boundary holds in practice is uncertain. A notable exemption is granted to firms that have begun actually building U.S. plants by October 1. In effect, this policy is designed to stimulate domestic drug manufacturing, but it also threatens to disrupt existing global supply chains.
The tariff move is being pitched as a “national security” measure and an industrial policy initiative, aimed at reducing U.S. dependence on foreign-sourced medications. However, the timing and scope have unsettled both global drugmakers and markets.
What’s Making Investors Panic About Indian Pharma Now
India is a global powerhouse in generics, and the United States is its single largest export market, accounting for nearly a third of Indian pharmaceutical exports. In FY 2025, pharma exports from India crossed USD 30 billion, with many leading players deriving between 30–50% of revenues from the U.S. market. India also supplies more than 45 % of generics and around 15% of biosimilars consumed in the U.S.
Though the tariffs are focused on branded and patented drugs, there is uncertainty over how complex generics, specialty biologics, or biosimilars will be classified. This ambiguity has rattled markets, as investors fear spillover effects.
Among the major Indian drugmakers:
- Dr. Reddy’s is viewed as particularly vulnerable, given its exposure to branded and specialty drugs.
- Sun Pharma also faces meaningful risk because of its specialty portfolio.
- Cipla is seen as relatively safer, since its U.S. exposure is weighted more toward generics.
- Biocon was caught in the broader sector sell-off due to its biosimilar business.
On September 26, all 20 constituents of the Indian pharma index declined, with the index itself slipping around 2.6 %. Sun Pharma alone fell by over 3 %. The broader Indian benchmarks also ended lower, weighed down by pressure in pharma and IT.
Impacts and Risks: Short-Term and Long-Term
Short-term pain is already visible: valuations are under stress, and stock volatility has risen sharply. For many companies, new capital expenditure plans may be put on hold until clarity emerges.
If the tariff regime is enforced as stated, the following outcomes appear likely:
- Margin compression – Indian drugmakers could see profitability weaken if they are forced to absorb costs to remain competitive.
- Supply chain disruption – Reduced shipments to the U.S. may cause shortages or higher prices for American consumers.
- Policy pushback – Exporters and governments may lobby for exemptions or new trade negotiations.
- Forced localization – Some Indian and global pharma firms may be compelled to invest in U.S.-based plants, but this would require significant capital and time.
- Market diversification – Indian firms may accelerate expansion into alternative markets such as Latin America, Africa, and Southeast Asia.
Despite the risks, it’s worth noting that India’s strength in generics could help cushion the blow if the tariff remains limited to patented products. But the uncertainty around classification and future policy adjustments continues to cast a shadow.
What Should Investors and Policymakers Watch?
- Regulatory clarity – How will the U.S. define branded versus complex generics?
- Exemption conditions – Will exemptions be permanent for firms building U.S. plants?
- Trade negotiations – Can India secure favorable terms or carve-outs for its exporters?
- Corporate strategy – Which companies will pivot fastest toward alternate markets or local U.S. investments?
- Valuation resets – Investors will be watching closely for earnings revisions and stock re-ratings in the months ahead.
Trump’s 100% tariff decision underscores a sharp shift in U.S. trade and industrial strategy, with far-reaching implications for global pharma. For Indian drugmakers, the immediate impact has been painful, with share prices tumbling and uncertainty clouding outlooks. While the bulk of India’s generic business may stay insulated, exposure to branded drugs, biosimilars, and specialty formulations puts several companies at risk.
For now, investors and policymakers will be watching for clarity on definitions, exemptions, and negotiations. Until then, uncertainty itself will weigh heavily on both the pharma sector and Dalal Street sentiment.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis – Research & Ranking. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.
